Industry News
Biotechnology Industry News
Nuvation Bio has backed off from…
Nuvation Bio has backed off from its plans to directly compare its brain cancer drug to Servier's Voranigo, instead opting to focus on patients who aren’t covered by the approved competitor.
Korean biosimilar specialist…
Korean biosimilar specialist Celltrion has penned a deal worth more than $740 million biobucks for two preclinical autoimmune assets from U.S. biotech Kaigene.
A new West Coast biotech has…
A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed with $82 million
Foresight Diagnostics shared…
Foresight Diagnostics shared insights into the evolving role of minimal residual disease (MRD) testing in precision oncology.
AI-powered platform streamlines…
AI-powered platform streamlines regulatory processes, boosts collaboration and accelerates drug development timelines.
Biotech leader outlines how early…
Biotech leader outlines how early strategic alignment, cross-functional collaboration and AI-driven insights are reshaping commercialization success.
AI-powered Derisq platform offers…
AI-powered Derisq platform offers biotech and investment firms a faster, more accurate way to assess clinical trial risk and improve capital efficiency
Tempero Bio has hit the brakes on…
Tempero Bio has hit the brakes on a phase 2-stage alcohol use disorder program while the biotech considers its options, according to the program’s partner.
FDA is said to be making a U-turn…
FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game changer.
Roche may have been exploring ways…
Roche may have been exploring ways to shuttle drugs to the brain for well over a decade, but that's not stopping the pharma from handing $55 million to Manifold Bio for a fresh route through
TScan Therapeutics is laying off…
TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor therapy biotech abandons a phase 1 solid tumor trial and focuses on patients with blood cancers.
Neurocrine Biosciences has penned…
Neurocrine Biosciences has penned a deal with China’s TransThera Sciences potentially worth more than $880 million in biobucks for inhibitors aimed at a red-hot inflammation target.
Pfizer has lived up to its threat…
Pfizer has lived up to its threat of taking legal action to prevent Metsera from slipping out of its grasp, but the obesity biotech also seems up for the fight.
Boehringer Ingelheim’s busy year…
Boehringer Ingelheim’s busy year of dealmaking is showing no signs of slowing, with the German pharma now turning to established partner CDR-Life for a new trispecific autoimmune antibody.
Rich Segal highlights the…
Rich Segal highlights the importance of early IPO preparation for companies in the biotech sector and underscores how Chinese biotech companies are increasingly shaping the global biotech landscape.
Neok Bio has exited stealth with…
Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into the clinic.
Welcome to the Fierce Biotech…
Welcome to the Fierce Biotech Graveyard, our annual ritual remembering the biotechs we lost in 2025 and those on the brink.
Nanobiotix is continuing to find…
Nanobiotix is continuing to find fresh ways to eke money out of its Johnson & Johnson-partnered, phase 3-stage cancer drug.
4DMT has sold the Asia-Pacific…
4DMT has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 million in cash to fund the asset’s phase 3 development.
Gilead has chosen a partner for…
Gilead has chosen a partner for lenacapavir in the race to develop low-frequency treatments for HIV. After comparing two phase 1 integrase strand transfer inhibitors, the Bay Area pharma has elected to pair GS-3242 with